Roche touts PhIII results of Avastin combo in brain cancer

Roche ($RHHBY), the biggest cancer drug provider in the world, has made progress in building on its blockbuster franchise for the anti-tumor drug Avastin with results of a Phase III study that shows the drug used in combination with radiation and chemotherapy improved progression-free survival in patients newly diagnosed with glioblastoma. Avastin is already approved for treatment of brain cancer as a standalone agent, but the latest results boost the company's case for using the drug with standard approaches to combat the aggressive tumors early. Article